Elucidating these molecular mechanisms and functions of BIN1 not only sheds light on the pathogenic progression of BLCA but also positions BIN1 as a potential novel biomarker and therapeutic target for BLCA diagnosis and treatment, particularly in metastatic cases. Here, BIN1 is linked to bladder transitional cell carcinoma.